Needham downgrades ISIS Pharmaceuticals, Inc. (Nasdaq: ISIS) from Strong Buy to Hold, after Mipomersen delays. The ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE